1
|
Marvizon JCG, Wang X, Lao LJ, Song B. Effect of peptidases on the ability of exogenous and endogenous neurokinins to produce neurokinin 1 receptor internalization in the rat spinal cord. Br J Pharmacol 2003; 140:1389-98. [PMID: 14623771 PMCID: PMC1574162 DOI: 10.1038/sj.bjp.0705578] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
The ability of peptidases to restrict neurokinin 1 receptor (NK1R) activation by exogenously applied or endogenously released neurokinins was investigated by measuring NK1R internalization in rat spinal cord slices. Concentration-response curves for substance P and neurokinin A were obtained in the presence and absence of 10 microm thiorphan, an inhibitor of neutral endopeptidase (EC 3.4.24.11), plus 10 microm captopril, an inhibitor of dipeptidyl carboxypeptidase (EC 3.4.15.1). These inhibitors significantly decreased the EC50 of substance P to produce NK1R internalization from 32 to 9 nm, and the EC50 of neurokinin A from 170 to 60 nm. Substance P was significantly more potent than neurokinin A, both with and without these peptidase inhibitors. In the presence of peptidase inhibitors, neurokinin B was 10 times less potent than neurokinin A and 64 times less potent than substance P (EC50=573 nm). Several aminopeptidase inhibitors (actinonin, amastatin, bacitracin, bestatin and puromycin) failed to further increase the effect of thiorphan plus captopril on the NK1R internalization produced by 10 nm substance P. Electrical stimulation of the dorsal root produced NK1R internalization by releasing endogenous neurokinins. Thiorphan plus captopril increased NK1R internalization produced by 1 Hz stimulation, but not by 30 Hz stimulation. Therefore, NEN and DCP restrict NK1R activation by endogenous neurokinins when they are gradually released by low-frequency firing of primary afferents, but become saturated or inhibited when primary afferents fire at a high frequency.
Collapse
Affiliation(s)
- Juan Carlos G Marvizon
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
| | | | | | | |
Collapse
|
2
|
Peptidases prevent mu-opioid receptor internalization in dorsal horn neurons by endogenously released opioids. J Neurosci 2003. [PMID: 12629189 DOI: 10.1523/jneurosci.23-05-01847.2003] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
To evaluate the effect of peptidases on mu-opioid receptor (MOR) activation by endogenous opioids, we measured MOR-1 internalization in rat spinal cord slices. A mixture of inhibitors of aminopeptidases (amastatin), dipeptidyl carboxypeptidase (captopril), and neutral endopeptidase (phosphoramidon) dramatically increased the potencies of Leu-enkephalin and dynorphin A to produce MOR-1 internalization, and also enhanced the effects of Met-enkephalin and alpha-neoendorphin, but not endomorphins or beta-endorphin. The omission of any one inhibitor abolished Leu-enkephalin-induced internalization, indicating that all three peptidases degraded enkephalins. Amastatin preserved dynorphin A-induced internalization, and phosphoramidon, but not captopril, increased this effect, indicating that the effect of dynorphin A was prevented by aminopeptidases and neutral endopeptidase. Veratridine (30 microm) or 50 mm KCl produced MOR-1 internalization in the presence of peptidase inhibitors, but little or no internalization in their absence. These effects were attributed to opioid release, because they were abolished by the selective MOR antagonist CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH(2)) and were Ca(2+) dependent. The effect of veratridine was protected by phosphoramidon plus amastatin or captopril, but not by amastatin plus captopril or by phosphoramidon alone, indicating that released opioids are primarily cleaved by neutral endopeptidase, with a lesser involvement of aminopeptidases and dipeptidyl carboxypeptidase. Therefore, because the potencies of endomorphin-1 and endomorphin-2 to elicit internalization were unaffected by peptidase inhibitors, the opioids released by veratridine were not endomorphins. Confocal microscopy revealed that MOR-1-expressing neurons were in close proximity to terminals containing opioids with enkephalin-like sequences. These findings indicate that peptidases prevent the activation of extrasynaptic MOR-1 in dorsal horn neurons.
Collapse
|
3
|
Abstract
Cholecystokinin (CCK) is a peptide originally discovered in the gastrointestinal tract, but also found in high density in the mammalian brain. This peptide has been shown to be involved in numerous physiological functions such as feeding behavior, central respiratory control and cardiovascular tonus, vigilance states, memory processes, nociception, emotional and motivational responses. CCK interacts with nanomolar affinites with two different receptors designated CCK(1) and CCK(2). Primarily, the functional role of these binding sites in the brain and the periphery has been investigated thanks to the development of potent and selective CCK receptor antagonists and agonists. However, several studies have yielded conflicting data. Knockout mice provide unique opportunities to analyse diverse aspects of gene function in vivo. This review highlights recent progress in our understanding of the role of CCK(1) and CCK(2) receptors obtained by using mice with genetic invalidation of CCK(1) or CCK(2) receptors or natural CCK receptors mutants. The limits of this approach is discussed and some results were compared to those obtained by pharmacological blockade of CCK receptors by selective antagonists.
Collapse
Affiliation(s)
- F Noble
- Département de Pharmacochimie Moléculaire et Structurale, INSERM U266 - CNRS UMR8600, UFR des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire 75270, Paris Cedex 06, France
| | | |
Collapse
|
4
|
Budai D, Fields HL. Endogenous opioid peptides acting at mu-opioid receptors in the dorsal horn contribute to midbrain modulation of spinal nociceptive neurons. J Neurophysiol 1998; 79:677-87. [PMID: 9463431 DOI: 10.1152/jn.1998.79.2.677] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Activation of neurons in the midbrain periaqueductal gray (PAG) inhibits spinal dorsal horn neurons and produces behavioral antinociception in animals and analgesia in humans. Although dorsal horn regions modulated by PAG activation contain all three opioid receptor classes (mu, delta, and kappa), as well as enkephalinergic interneurons and terminal fields, descending opioid-mediated inhibition of dorsal horn neurons has not been demonstrated. We examined the contribution of dorsal horn mu-opioid receptors to the PAG-elicited descending modulation of nociceptive transmission. Single-unit extracellular recordings were made from rat sacral dorsal horn neurons activated by noxious heating of the tail. Microinjections of bicuculline (BIC) in the ventrolateral PAG led to a 60-80% decrease in the neuronal responses to heat. At the same time, the responses of the same neurons to iontophoretically applied NMDA or kainic acid were not consistently inhibited. The inhibition of heat-evoked responses by PAG BIC was reversed by iontophoretic application of the selective mu-opioid receptor antagonists, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP). A similar effect was produced by naloxone; however, naloxone had an excitatory influence on dorsal horn neurons in the absence of PAG-evoked descending inhibition. This is the first demonstration that endogenous opioids acting via spinal mu-opioid receptors contribute to brain stem control of nociceptive spinal dorsal horn neurons. The inhibition appears to result in part from presynaptic inhibition of afferents to dorsal horn neurons.
Collapse
Affiliation(s)
- D Budai
- Departments of Neurology and Physiology and the W. M. Keck Foundation Center for Integrative Neuroscience, University of California, San Francisco, California 94143-0114, USA
| | | |
Collapse
|
5
|
Saria A, Hauser KF, Traurig HH, Turbek CS, Hersh L, Gerard C. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice. Neurosci Lett 1997; 234:27-30. [PMID: 9347938 DOI: 10.1016/s0304-3940(97)00660-5] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Neutral endopeptidase EC 3.4.24.11 (NEP) is localized in peptidergic neurons and various colocalized peptides or other humoral mediators may serve as substrates. Target disruption of the NEP gene was reported to enhance the lethal response to endotoxin shock in mice. We examined thermonociceptive thresholds and enkephalin (ENK) tissue levels in transgenic NEP (-/-) and control wild type NEP (+/+) mice. Hot plate (52 degrees C) latency was 13.1 +/- 1.4 s in NEP (+/+) mice (n = 16) while latency increased significantly (P = 0.031) to 17.7 +/- 1.6 s in NEP (-/-) mice. Naloxone (10 mg/kg) had no effect on hot plate latency in NEP (+/+) mice (12.5 s, n = 8), but significantly decreased the latency in NEP (-/-) mice compared to untreated NEP (-/-) deficient mice (10.5 s, n = 8). Morphine (3 or 10 mg/kg) analgesic response was similar in knockout mice and wild type mice. Methionine-ENK (MET-ENK) and leucine-ENK (LEU-ENK) levels were determined in extracts from cortex, brain stem, hypothalamus, striatum, spinal cord, trigeminal ganglion and heart in treated and untreated mice. ENK-levels varied in a regionally-dependent manner and were significantly decreased in hypothalamus and spinal cord. We conclude that deletion of the NEP gene results in an opioid-related increase in thermonociceptive threshold. Regional differences in opioid metabolism indicate that NEP evokes tissue-specific patterns of ENK-regulation. NEP selectively controls opioid biosynthesis in hypothalamus and spinal cord presumably by feedback regulation.
Collapse
Affiliation(s)
- A Saria
- Neurochemical Laboratory, Clinic of Psychiatry, Innsbruck, Austria.
| | | | | | | | | | | |
Collapse
|
6
|
Yamamori Y, Saito Y, Kaneko M, Kirihara Y, Sakura S, Kosaka Y. Antinociceptive effects of ONO-9902, an enkephalinase inhibitor, after visceral stress condition in rats. Can J Anaesth 1996; 43:1175-9. [PMID: 8922777 DOI: 10.1007/bf03011848] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE The present study was designed to examine the antinociceptive effects of orally administered ONO-9902, an enkephalinase inhibitor, on both somatic and visceral pain after visceral stress conditions. METHODS Twenty six male rats were examined. Tail-flick (TF) and colorectal distension (CD) tests were used to determine somatic and visceral antinociceptive effects, respectively. Measurements were performed in rats under immediate post-stress conditions (group ST; n = 14) and in rats nor under stress conditions (group NST; n = 12). In the stressed group, the same device, CD, for visceral antinociceptive effects was used for visceral stress and was applied with an intracolonic pressure of 60 mmHg for 20 min after drug administration. The TF latency and CD threshold were measured before and at 30, 40, 50, 60 and 90 min after administration of ONO-9902 300 mg.kg-1 or distilled water. RESULTS Orally administered ONO-9902 did not produce any changes in the % maximum possible effect (%MPE) in either TF or CD tests in the unstressed group. In the stressed group, %MPE in the CD test increased 18% and 31% at 30 and 40 min, respectively, after oral administration of ONO-9902 compared with the control group (P < 0.05). However, %MPE to TF test did not alter even after the CD-induced stress condition. CONCLUSION These results suggest that ONO-9902 may have analgesic effects on visceral pain but not on somatic pain under immediate post-stress conditions.
Collapse
Affiliation(s)
- Y Yamamori
- Department of Anesthesiology, Shimane Medical University, Izumo, Japan
| | | | | | | | | | | |
Collapse
|
7
|
Valverde O, Fournié-Zaluski MC, Roques BP, Maldonado R. Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids. Eur J Pharmacol 1996; 312:15-25. [PMID: 8891574 DOI: 10.1016/0014-2999(96)00437-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The complete inhibitor of the enkephalin degrading enzymes, RB 101, N-{(R,S)-2-benzyl-3[(S)-(2-amino-4-methylthio)butyldithio]-1- oxopropyl}-L-phenylalanine benzyl ester, which crosses the blood-brain barrier, induced antinociceptive effects similar to those of exogenous opiates. The almost complete absence of tolerance and dependence after chronic administration of RB 101 is therefore due to limited stimulation of opioid receptors by 'protected' endogenous enkephalins. In order to clarify the mechanisms involved in these response, we have investigated the participation of several brain structures in the antinociceptive effects induced by systemic administration of morphine or RB 101. Rats were implanted with bilateral cannulae into the ventro-basal thalamus, central amygdala and periaqueductal gray matter, or with a cannula into the raphe magnus nucleus. The antinociceptive responses induced by systemic morphine or RB 101 were measured by using the tail-electrical stimulation test, where three different thresholds were determined: motor response, vocalization and vocalization post-discharge. The ability of the opioid receptor antagonist methylnaloxonium to block these antinociceptive responses was evaluated after local injection into the different brain structures. The blockade of morphine- and RB 101-induced antinociception was similar, and was stronger when methylnaloxonium was injected into the periaqueductal gray matter and raphe magnus nucleus than when it was injected into the ventro-basal thalamus and amygdala. These results suggest that brain structures related to the control of pain seem to be the same for the antinociception induced by exogenous opiates and endogenous opioids.
Collapse
Affiliation(s)
- O Valverde
- Département de Pharmacochimie Moléculaire et Structurale U266 INSERM, URA D 1500 URF des Sciences Pharmaceutiques et Biologiques, Faculté de Pharmacie, Université René Descartes, Paris, France
| | | | | | | |
Collapse
|
8
|
Sagratella S. Enkephalinase inhibition and hippocampal excitatory effects of exogenous and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:965-78. [PMID: 7824762 DOI: 10.1016/0278-5846(94)90123-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
1. The relationships between the in vivo and in vitro epileptogenic effects of opioids or enkephalins and the electrophysiological activity of inhibitors of endogenous enkephalinase were analyzed. 2. The functional effects of the inhibition of the endogenous enkephalinase has been compared with the role of the endogenous opioid peptidergic system in the control of neuronal excitability.
Collapse
Affiliation(s)
- S Sagratella
- Laboratorio di Farmacologia, Istituto Superiore di Sanità, Roma, Italy
| |
Collapse
|
9
|
Agmo A, Gomez M, Irazabal Y. Enkephalinase inhibition facilitates sexual behavior in the male rat but does not produce conditioned place preference. Pharmacol Biochem Behav 1994; 47:771-8. [PMID: 8029244 DOI: 10.1016/0091-3057(94)90276-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The effects of two enkephalinase inhibitors, SCH 34826 and phospho-leu-phe, on male rat sexual behavior and conditioned place preference were evaluated. SCH 34826, administered intraperitoneally, reduced the ejaculation latency to both the first and second ejaculation at a dose of 30 mg/kg. This dose also reduced the first postejaculatory interval. No other effect was obtained with this drug. Phospho-leu-phe, administered intracerebroventricularly, increased mount and intromission latency at doses of 50 and 100 micrograms. A dose of 25 micrograms reduced the latency to the first ejaculation as well as the number of preejaculatory intromissions. The postejaculatory interval was also reduced at this dose. SCH 34826, 100 and 30 mg/kg, and phospho-leu-phe, 25 micrograms, had no effect in the conditioned place preference procedure. These observations seem to suggest that there is no functionally relevant tonic release of enkephalins. Therefore, the effects obtained on sexual behavior may indicate that enkephalins are released before and during the course of sexual activity. The function of such a release could be to facilitate ejaculatory mechanisms in the way found in the present studies. Previous work has shown that ejaculation-induced reward is opioid dependent, further supporting the hypothesis of opioid release during sexual activity. Taken together, these data suggest an important role for opioids, probably enkephalins, in the physiological control of sexual behavior.
Collapse
Affiliation(s)
- A Agmo
- Department of Psychology, Universidad Anahuac, Mexico City, Mexico
| | | | | |
Collapse
|
10
|
Young RF, Bach FW, Van Norman AS, Yaksh TL. Release of beta-endorphin and methionine-enkephalin into cerebrospinal fluid during deep brain stimulation for chronic pain. Effects of stimulation locus and site of sampling. J Neurosurg 1993; 79:816-25. [PMID: 8246048 DOI: 10.3171/jns.1993.79.6.0816] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The authors systematically studied the release of the endogenous opioid peptides beta-endorphin and methionine (met)-enkephalin into the cerebrospinal fluid (CSF) during deep brain stimulation in patients suffering from otherwise intractable chronic pain. Nine patients were included in the study; six had stimulation electrodes placed in both the periventricular gray matter (PVG) and the thalamic nucleus ventralis posterolateralis (VLP) and three in the PVG only. Immunoreactivity of beta-endorphin and met-enkephalin (beta-EPir and MEir, respectively) was measured by radioimmunoassays in ventricular and lumbar CSF samples obtained before, during, and after stimulation. Prestimulation concentrations of beta-EPir and MEir were lower in ventricular than in lumbar CSF (6.6 +/- 0.5 vs. 13.7 +/- 1.0 pmol/liter, p = 0.0001, for beta-EPir; 33.6 +/- 5.1 vs. 48.3 +/- 3.2 pmol/liter, p < 0.05, for MEir). Ventricular CSF concentrations of both beta-EPir and MEir increased significantly during PVG stimulation, whereas VPL stimulation was without effect. No changes were seen in lumbar CSF levels of the peptides during stimulation in either site. A significant inverse relationship was found between the "during:before stimulation" ratios of visual analog scale ratings and beta-EPir levels during PVG stimulation. The beta-EPir and MEir concentration during:before stimulation ratios were positively correlated, whereas no correlation was present in prestimulation samples from ventricular or lumbar CSF. High-performance liquid chromatography of ventricular CSF pools obtained during PVG stimulation revealed that major portions of beta-EPir and MEir eluted as synthetic beta-endorphin and met-enkephalin, respectively, thus documenting the release of beta-endorphin and met-enkephalin into ventricular CSF during PVG stimulation. The finding of a direct relationship between beta-EPir release and pain alleviation may suggest a role for beta-endorphin in the analgesic mechanism of PVG stimulation.
Collapse
Affiliation(s)
- R F Young
- Department of Neurological Surgery, University of California Irvine School of Medicine, Orange
| | | | | | | |
Collapse
|
11
|
Otero MJ, Iglesias T, Fuentes JA. Hypoalgesic action of bestatin analogues that inhibit central aminopeptidases, but not neutral endopeptidase. Neuropeptides 1993; 25:175-82. [PMID: 8247255 DOI: 10.1016/0143-4179(93)90100-o] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Two analogues of the aminopeptidase inhibitor bestatin, Z 4212 (N-[(2S, 3R)-3-Amino-2-hydroxy-4-(4-methylsulphonyl-phenyl)-1-oxobutyl]-1- aminocyclopentanecarboxylic) and Z 1796 ((2S)-N-[(2S,3R)-3-Amino-2-hydroxy-4-(4-methylsulphonyl-phenyl)-1- oxobutyl]-L-leucine) were found to behave as hypoalgesics when intracerebroventricularly (i.c.v.) administered to mice in the hot-plate test. At high doses, Z 4212 was also found to reduce the pain threshold after intraventricular (i.v.) administration. Hypoalgesia induced by bestatin analogues was prevented by prior treatment with the opiate receptor blocker naloxone. Thiorphan, a potent inhibitor of NEP, was found to enhance the hypoalgesic effect of low doses of either Z 4212 or Z 1796. These results indicate that both the major opioid-degrading peptidases, i.e. aminopeptidases and neutral endopeptidase (NEP), are individually implicated in the hypoalgesia induced by peptidase inhibitors. In vitro studies showed that these new bestatin analogues readily inhibit aminopeptidases in membranes from mouse c. striatum whereas more than 1000 times the concentration was required for NEP to be blocked. Ex vivo experiments showed that, at variance with bestatin, the hypoalgesic action of Z 4212 or Z 1796 appeared to implicate central aminopeptidases but not NEP, so partially sparing the metabolism of other NEP substrates that might produce additional alterations (substance P and ANP). On the basis of the antitumour and immunomodulatory actions of bestatin, these new analogues might be potentially useful as mixed antitumour and hypoalgesic agents in malignancy.
Collapse
Affiliation(s)
- M J Otero
- Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain
| | | | | |
Collapse
|
12
|
Proietti ML, Sagratella S, Frank C, Trampus M, Scotti de Carolis A. An in vitro study on the hippocampal electrophysiological properties of enkephalinase inhibitors in rats. Pharmacol Biochem Behav 1991; 39:119-21. [PMID: 1924493 DOI: 10.1016/0091-3057(91)90407-s] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The effects of two enkephalinase inhibitors were studied on the CA1 and dentate hippocampal extracellular field potentials (FPs). The enkephalinase inhibitors thiorphan and SCH 32615, at a concentration of 1-500 microM, failed to significantly affect CA1 and dentate FPs. Thiorphan and SCH 32615, at a concentration of 150 microM, were able to potentiate the enkephalin-induced epileptiform bursting, inducing an increase in the bursting duration and in the number of spikes per burst due to 3.5 microM DAEAM or 0.20 microM DAGO. The results suggest: 1) the potentiation of an electrophysiological opiate receptor-mediated response by enkephalinase inhibitors; 2) the inability to show a direct effect on the basal CA1FP as a result of the inhibition of the endogenous enkephalinase.
Collapse
Affiliation(s)
- M L Proietti
- Pharmacology Department, Istituto Superiore di Sanitá, Roma, Italy
| | | | | | | | | |
Collapse
|
13
|
Giorgi O, Pibiri MG, Ongini E, Trampus M, Biggio G. The neutral endopeptidase-24.11 (enkephalinase) inhibitor, SCH 32615, increases dopamine metabolism in the nucleus accumbens of the rat. Eur J Pharmacol 1991; 196:137-42. [PMID: 1874283 DOI: 10.1016/0014-2999(91)90419-q] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
SCH 32615 is a novel inhibitor of the enzyme, neutral endopeptidase (NEP, E.C. 3.4.24.11), the so called 'enkephalinase', which plays a functional role in the degradation of [Met5]- and [Leu5]enkephalin. The present study was designed to assess whether SCH 32615 is able to modify the activity of dopaminergic neurons as reflected by changes in the content of the major dopamine metabolite, dihydroxyphenylacetic acid (DOPAC), in three different areas of the rat brain: the nucleus accumbens, the striatum, and the prefrontal cortex. When administered at analgesically active doses (1-100 mg/kg s.c., 60 min before killing), SCH 32615 induced a dose-dependent increase in dopamine metabolism in the nucleus accumbens but was ineffective in the striatum and in the prefrontal cortex. This effect appears to be mediated via opioid receptors, since it was completely prevented by naloxone (5 mg/kg s.c.). The increase in DOPAC content in the prefrontal cortex elicited by foot-shock was unaffected by pretreatment with SCH 32615. In the nucleus accumbens, dopamine metabolism was increased to the same extent by foot-shock and SCH 32615 administered separately, but these effects were not additive, suggesting that SCH 32615 and foot-shock act via a common mechanism. Taken together, these results support the hypothesis that inhibition of the in vivo degradation of enkephalins induced by the systemic administration of SCH 32615 increases the enkephalinergic tone in the central nervous system and thereby activates the mesolimbic dopaminergic neurons.
Collapse
Affiliation(s)
- O Giorgi
- Department of Experimental Biology, University of Cagliari, Italy
| | | | | | | | | |
Collapse
|
14
|
Trampus M, Ongini E, Varani K, Borea PA. The neutral endopeptidase-24.11 inhibitor SCH 34826 does not change opioid binding but reduces D1 dopamine receptors in rat brain. Eur J Pharmacol 1991; 194:17-23. [PMID: 1647961 DOI: 10.1016/0014-2999(91)90118-a] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effect of repeated administration of the neutral endopeptidase-24.11 (NEP) inhibitor SCH 34826 on the kinetic properties of opioid and dopamine binding in the rat cerebral cortex and striatum was investigated. SCH 34826, given at 100 and 300 mg/kg orally twice a day for 14 days, did not alter either Bmax or Kd for the mu, delta, or kappa opioid receptor type in the cortex, as measured by studying binding parameters for the mu-selective ligand [3H][D-Ala2, Me-Phe4,Gly(ol)5]enkephalin (DAGO), the delta-selective ligand [3H][D-Pen2,D-Pen5]enkephalin (DPDPE) and the kappa ligand [3H]ethylketazocine (EKC). SCH 34826 reduced significantly the number of D1 dopamine receptors labeled with [3H]SCH 23390 in the striatum (Bmax was 90 and 84% of controls at 100 and 300 mg/kg, respectively). The number of D2 receptors, measured by [3H]spiperone binding was unaltered. The Kd values for both receptor types were not affected. The data demonstrate that chronic inhibition of enkephalin degradation by SCH 34826 does not alter opioid receptors, whereas it reduces the number of D1 receptors. These findings provide further support for the role of opioids in modulating central dopaminergic systems. As a reduction in the number of D1 receptors is an effect common to antidepressant treatments, the antidepressant potential of NEP inhibitors should be investigated.
Collapse
MESH Headings
- Analgesics/pharmacology
- Animals
- Brain Chemistry/drug effects
- Dioxolanes/pharmacology
- Dipeptides/pharmacology
- Dopamine Antagonists
- Enkephalin, Leucine-2-Alanine/pharmacology
- Etorphine/pharmacology
- Kinetics
- Male
- Morphine/pharmacology
- Neprilysin/antagonists & inhibitors
- Rats
- Rats, Inbred Strains
- Receptors, Dopamine D1
- Receptors, Dopamine D2
- Receptors, Opioid/drug effects
- Receptors, Opioid, delta
- Receptors, Opioid, mu
- Receptors, sigma
Collapse
Affiliation(s)
- M Trampus
- Research Laboratories, Schering-Plough S.p.A., Milan, Italy
| | | | | | | |
Collapse
|
15
|
Scotti De Carolis A, Sagratella S, Frank C, Trampus M, Proietti ML. An in vitro study on the hippocampal epileptogenic properties of enkephalins and enkephalinase inhibitors in rats. GENERAL PHARMACOLOGY 1991; 22:651-7. [PMID: 1657689 DOI: 10.1016/0306-3623(91)90072-e] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
1. The effects of enkephalins and enkephalinase inhibitors were studied in CA1 area in rat hippocampal slices. 2. The data demonstrate a prevalent involvement of mu opiate receptors in the epileptogenic properties of enkephalins. 3. A potentiation of the mu opiate receptor-mediated epileptogenic response by enkephalinase inhibitors has been shown. 4. The results also show an inability to affect basal CA1 field potentials by inhibition of endogenous endopeptidase.
Collapse
MESH Headings
- Animals
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalin, Methionine/analogs & derivatives
- Enkephalin, Methionine/pharmacology
- Enkephalins/pharmacology
- Epilepsy/chemically induced
- Epilepsy/physiopathology
- Hippocampus/drug effects
- Hippocampus/physiology
- In Vitro Techniques
- Male
- Morphine/pharmacology
- Neprilysin/antagonists & inhibitors
- Rats
- Rats, Inbred Strains
- Receptors, Opioid/drug effects
- Receptors, Opioid/physiology
- Receptors, Opioid, mu
Collapse
|
16
|
al-Rodhan N, Chipkin R, Yaksh TL. The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala. Brain Res 1990; 520:123-30. [PMID: 2207626 DOI: 10.1016/0006-8993(90)91697-f] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The local effects of SCH-32615, an inhibitor of enkephalinase (EC 3.4.24.11) on the hot-plate (HP) and tail-flick (TF) responses were examined following unilateral intracerebral microinjection into the periaqueductal brain (PAG), the medial ventral medulla (VM) and bilateral microinjection into the amygdala (AM) of the rat. In the PAG and VM, SCH-32615 resulted in a dose-dependent increase in HP and TF response latencies over a dose range of 1-30 micrograms with the ED50 values (micrograms) being PAG-TF = 17; PAG-HP = 11; VM-TF = 7; VM-HP = 6. In the AM, dose-dependent increases were only observed on the HP. (ED50 (micrograms) HP = 17). Peak effects were observed within 10 min and response latencies remained elevated for 45-60 min. Injections of SCH-32615 at sites outside of the PAG or VM were considerably less effective. All antinociceptive effects were antagonized by naloxone (1 mg/kg, i.p.). Twenty-four hours following the microinjection of beta-funaltrexamine (an irreversible opioid antagonist) into the PAG or the VM, the effects of SCH-32615 in the PAG were virtually abolished while in the VM, its effects were only moderately reduced. These data suggest that in the presence of a strong thermal stimulus, the behavioral response is subject to a tonically active or stimulus-evoked modulation by the local release in the PAG, VM and AM of an agent, presumably an enkephalin peptide, the degradation of which is altered by enkephalinase inhibition.
Collapse
Affiliation(s)
- N al-Rodhan
- Department of Neurosurgery, Mayo Clinic, Rochester, MN 55905
| | | | | |
Collapse
|
17
|
Oshita S, Yaksh TL, Chipkin R. The antinociceptive effects of intrathecally administered SCH32615, an enkephalinase inhibitor in the rat. Brain Res 1990; 515:143-8. [PMID: 2357551 DOI: 10.1016/0006-8993(90)90588-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The presence of opioid receptors and enkephalin-releasing neurons in the spinal dorsal horn prompted us to examine whether an enkephalinase inhibitor, SCH32615, given intrathecally would alter the response of the rat on several nociceptive endpoints: 49 degrees C hot plate (HP), 52 degrees C HP; tail flick (TF) and the paw pressure (PP) test. SCH (16-320 nmol, i.t.) resulted in a submaximal dose-dependent increase in the 49 degrees C HP, 52 degrees C HP, TF, and PP measures with the respective ED50 values being 40, 74, 68 and 83 nmol, respectively. AT 320 nmol, no additional increment in effect was observed. Concurrent examination of the effects of 0.1-10 nmol morphine on the 49 degrees C HP, 52 degrees C HP, TF and PP measures revealed i.t. ED50 values of 0.2, 0.8, 0.9 and 0.6 nmol, respectively, with the maximum dose leading to a complete block on all measures. The effects of SCH were totally reversed by naloxone (1 mg/kg, i.p.), a dose which had no detectable effect upon baseline nociceptive response measures. The effects of SCH, even at the highest dose were not accompanied by motor dysfunction or catalepsy. These results are consistent with the hypothesis that high-threshold thermal and mechanical stimuli will evoke the release of an opioid in the spinal space, the metabolism of which is significantly influenced by enkephalinase inhibition.
Collapse
Affiliation(s)
- S Oshita
- Department of Anesthesiology, University of California, San Diego, La Jolla 92093
| | | | | |
Collapse
|
18
|
Trampus M, Conti A, Marzanatti M, Monopoli A, Ongini E. Effects of the enkephalinase inhibitor SCH 34826 on the sleep-waking cycle and EEG activity in the rat. Neuropharmacology 1990; 29:199-205. [PMID: 2325830 DOI: 10.1016/0028-3908(90)90002-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The sedative effect of SCH 34826, an enkephalinase inhibitor, was evaluated by studying electroencephalographic (EEG) activity, behaviour and the sleep-waking cycle in the rat. The reference opioid, morphine, was used for comparison. After administration of morphine (10 mg/kg s.c.) the rats were motionless and stuporous at first and then hyperactive. An increase of slow wave sleep, at the expense of both wakefulness and REM sleep was recorded, with high-amplitude slow wave bursts appearing in the EEG tracings during the waking, albeit stuporous, phase. Relative spectral power in the 1-4 and 12-16 Hz bands was increased and there was a shift of the dominant frequency to a lower frequency. The specific opioid antagonist, naltrexone, readily reversed most of these effects. The drug SCH 34826 (10-100 mg/kg p.o.) had no effect on the parameters examined; large doses (300 and 1000 mg/kg p.o.) induced restlessness in some animals, resulting in increased waking. This effect was antagonized by naltrexone. The data indicate that SCH 34826, at doses far greater than those proposed for clinical use, is devoid of sedative liability and does not induce any of the behavioural or EEG effects typical of morphine.
Collapse
Affiliation(s)
- M Trampus
- Research Laboratories, Schering-Plough S.p.A., Milan, Italy
| | | | | | | | | |
Collapse
|